help button home button The Oncologist
HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow eLetters: Submit a response to this article
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Reprints/Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Armstrong, D.
Right arrow Articles by O'Reilly, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Armstrong, D.
Right arrow Articles by O'Reilly, S.
The Oncologist, Vol. 3, No. 1, 4–10, February 1998
© 1998 AlphaMed Press

Clinical Guidelines for Managing Topotecan-Related Hematologic Toxicity

Deborah Armstrong, Seamus O'Reilly

Johns Hopkins Oncology Center, Baltimore, Maryland, USA

Correspondence: Seamus O'Reilly, M.D., Ph.D., Johns Hopkins Oncology Center, 600 North Wolfe Street, Room 137, Baltimore, Maryland 21287-8934, USA. Telephone: 410-614-4192; Fax: 410-955-0125; email: oreilse{at}welchlink.welch.jhu.edu

Purpose: Topotecan, a semisynthetic water-soluble camptothecin analog, was recently approved as a second-line treatment for women with ovarian cancer. In clinical trials, hematologic toxicity has been the predominant toxicity associated with its use. The purpose of this article is to provide guidelines on the clinical management of these toxicities.

Methods: The guidelines on the management of hematologic toxicities associated with topotecan therapy for advanced ovarian cancer patients were established through a review and analysis of phase I, II, and III clinical trials.

Results: In phase I studies, noncumulative neutropenia was the predominant toxicity associated with topotecan therapy. In subsequently conducted phase II trials, thrombocytopenia related to prior carboplatin and alkylating agent therapies has become a prominent toxicity, and neutropenia has been more severe than anticipated from phase I studies. The risk for both toxicities relates to the extent of prior myelosuppressive chemotherapy and to renal impairment. These toxicities can be managed through the identification of high-risk patients and implementation of appropriate prophylactic measures. Such measures include dose reductions or the use of hematopoietic growth factors. For patients with persistently low blood cell parameters, transfusion therapy remains a viable option.

Conclusion: Hematologic toxicities associated with topotecan therapy are noncumulative. Consequently, once a dosing regimen is established, toxicity patterns are predictable. Pretreatment assessment of the nature and toxicities of prior therapy and renal function should assist the clinician in preventing complications caused by the myelosuppressive effects of topotecan therapy.

Key Words. Topotecan • Topoisomerase I inhibitor • Chemotherapy • Ovarian cancer




This article has been cited by other articles:


Home page
 The OncologistHome page
D. K. Armstrong, D. Spriggs, J. Levin, R. Poulin, and S. Lane
Hematologic Safety and Tolerability of Topotecan in Recurrent Ovarian Cancer and Small Cell Lung Cancer: An Integrated Analysis
Oncologist, October 1, 2005; 10(9): 686 - 694.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
P. Sabbatini, C. Aghajanian, D. Dizon, S. Anderson, J. Dupont, J. V. Brown, W. A. Peters, A. Jacobs, A. Mehdi, S. Rivkin, et al.
Phase II Study of CT-2103 in Patients With Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma
J. Clin. Oncol., November 15, 2004; 22(22): 4523 - 4531.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
D. K. Armstrong
Topotecan Dosing Guidelines in Ovarian Cancer: Reduction and Management of Hematologic Toxicity
Oncologist, February 1, 2004; 9(1): 33 - 42.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
S. Wadler, D. E. Levy, S. T. Lincoln, G. S. Soori, J. C. Schink, and G. Goldberg
Topotecan Is an Active Agent in the First-Line Treatment of Metastatic or Recurrent Endometrial Carcinoma: Eastern Cooperative Oncology Group Study E3E93
J. Clin. Oncol., June 1, 2003; 21(11): 2110 - 2114.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
T. J. Herzog
Update on the Role of Topotecan in the Treatment of Recurrent Ovarian Cancer
Oncologist, October 1, 2002; 7(90005): 3 - 10.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
C. J. Dunton
Management of Treatment-Related Toxicity in Advanced Ovarian Cancer
Oncologist, October 1, 2002; 7(90005): 11 - 19.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
D. K. Armstrong
Relapsed Ovarian Cancer: Challenges and Management Strategies for a Chronic Disease
Oncologist, October 1, 2002; 7(90005): 20 - 28.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
E. K. Rowinsky
Weekly Topotecan: An Alternative to Topotecan's Standard Daily x 5 Schedule?
Oncologist, August 1, 2002; 7(4): 324 - 330.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
S. O'Reilly
Topotecan: What Dose, What Schedule, What Route?
Clin. Cancer Res., January 1, 1999; 5(1): 3 - 5.
[Full Text] [PDF]

Home page
 The OncologistHome page
J.-F. Héron
Topotecan: An Oncologist's View
Oncologist, December 1, 1998; 3(6): 390 - 402.
[Abstract] [Full Text]

Home page
 The OncologistHome page
H. A. Burris III
Topotecan: Incorporating It Into the Treatment of Solid Tumors
Oncologist, February 1, 1998; 3(1): 1 - 3.
[Full Text]


HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
THE ONCOLOGIST STEM CELLS CME ALPHAMED PRESS JOURNALS


Copyright © 1998 by AlphaMed Press.